Circular Genomics provides RNA-based diagnostics and therapeutics for treating depression and other psychiatric and neurological conditions. The company has developed circular RNA-based genomic assays that serve as biomarkers to predict therapeutic response for individuals with psychiatric disorders, enabling personalized treatment selection. Founded in 2021 and headquartered in Albuquerque, United States, Circular Genomics has raised approximately $29M in Series A funding from investors including Mountain Group Partners, The University of New Mexico, Cottonwood Technology Fund, Tramway Venture Partners, and Alzheimer's Drug Discovery Foundation. The company employs 19 people and leverages circular RNA biomarkers, which are more stable than linear RNA, to develop diagnostic tests that can predict patient response to antidepressant medications, addressing the trial-and-error approach that currently characterizes psychiatric drug selection.
← All startups
Circular Genomics
Series ACircular Genomics provides RNA-based diagnostics and therapeutics for treating depression and other psychiatric and neurological conditions. The company has developed circular RNA-based genomic assays that serve as biomarkers to predict therapeutic response for individuals with psychiatric disorders, enabling personalized treatment selection. Founded in 2021 and headquartered in Albuquerque, United States, Circular…
About
Business model
Neurology > In-Vitro Diagnostics > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Theranostics
Institutional investors
Mountain Group PartnersThe University of New MexicoCottonwood Technology FundTramway Venture PartnersAlzheimer's Drug DiscoveryHIP Fund
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.